Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
Over the last decade several attempts have been made to generate an active drug from an inactive precursor, by the action of an enzyme present predominantly at the tumour site. The aim was to develop a new, less cytotoxic strategy for the treatment of cancer, by exploiting properties distinguishing neoplastic and normal cells. In fact, monoclonal antibodies were used to carry enzymes at the tumour sites, in a two-step approach, known as Antibody Directed Enzyme Prodrug Therapy (ADEPT). We reviewed the experimental and clinical considerations of this strategy and we presented its problems and limitations. We concluded that ADEPT holds the potential of an effective and relatively non-toxic treatment of cancer and it is expected that the research which is in progress will make ADEPT an important element of the anticancer armament.
Syrigos
K N
KN
Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, London, U.K.
Epenetos
A A
AA
D000469:Alkaline Phosphatase / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002268:Carboxypeptidases / Q000008:administration & dosage; D004798:Enzymes / Q000008:administration & dosage*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009601:Nitroreductases / Q000008:administration & dosage; D011355:Prodrugs / Q000008:administration & dosage* / Q000378:metabolism; D001617:beta-Glucosidase / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D004798:Enzymes; D011355:Prodrugs; D009601:Nitroreductases; D000469:Alkaline Phosphatase; D001617:beta-Glucosidase; D002268:Carboxypeptidases